PCM
ANEB

Praetorian Capital Management’s Anebulo Pharmaceuticals ANEB Stock Holding History

Praetorian Capital Management’s Portfolio ANEB Stock Details ANEB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-180,005
Closed -$436K – 23
2022
Q4 		$436K Buy
+180,005
New +$474K 0.35% 11

Other funds holding ANEB

2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
LA
LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Praetorian Capital Management's ANEB Position: Q1 2023 in Review

Praetorian Capital Management sold out of Anebulo Pharmaceuticals (ANEB) in Q1 2023, closing a stake of 180,005 shares — an estimated $436K sold.

Praetorian Capital Management first reported a position in ANEB in Q4 2022 and held it in 1 quarter. The position peaked at $436K in Q4 2022. 10 funds tracked by Wall St. Rank hold ANEB as of Q1 2023.

  • Praetorian Capital Management reported no remaining Anebulo Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Praetorian Capital Management sold 180,005 Anebulo Pharmaceuticals shares in Q1 2023, an estimated $436K.
  • Praetorian Capital Management first reported a position in Anebulo Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Praetorian Capital Management's Anebulo Pharmaceuticals position peaked at $436K in Q4 2022.
  • 10 funds tracked by Wall St. Rank held Anebulo Pharmaceuticals as of Q1 2023.

Based on Praetorian Capital Management's 13F filing for Q1 2023, filed 8 May 2023.